These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26472104)

  • 1. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
    Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Zhang Y; Li Y; Cai Y; Wang K; Li H
    Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
    Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
    Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
    Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
    Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
    BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
    Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
    Yu X; Guo G; Li X; Zhang C; Huang L; Fang D; Song Y; Zhang X; Zhou L
    Medicine (Baltimore); 2015 Aug; 94(34):e1361. PubMed ID: 26313773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
    Joshi A; Ramaswamy A; Noronha V; Patil VM; Chandrasekharan A; Goel A; Sahu A; Sable N; Agrawal A; Menon S; Prabhash K
    Indian J Cancer; 2016; 53(3):423-428. PubMed ID: 28244475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
    Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.